News|Articles|July 7, 2026

Q2 2026 Recap: Gastroenterology News & Updates

Catch up on Q2 GI headlines you may have missed, including an expanded FDA approval for linaclotide, a submission for risankizumab SC induction in Crohn’s, and more.

The second quarter of 2026 brought significant momentum in gastroenterology, with regulatory milestones, promising late-stage clinical trial results, and continued innovation across inflammatory bowel disease and pediatric gastrointestinal care. From new US Food and Drug Administration (FDA) approvals to advances in ulcerative colitis therapeutics, the quarter reflected a rapidly evolving treatment landscape aimed at improving outcomes for patients with complex GI diseases.